

WP2372422



Pfizer ApS
Lautrupvang 8
DK-2750 Ballerup
Tlf.: 44 20 11 00
Fax: 44 20 11 01
www.pfizer.dk
CVR.nr. 66351912

Department of Oncology
Aarhus University Hospital
Palle Juul-Jensens Boulevard 99
8200 Aarhus N
VAT-no. 29 76 29 29, CVR-no. 29 19 09 25
Att.: Marianne Ingerlev Holt

Ballerup, 11 November 2019

Agreement on support to: Further Development and Maintenance of Oncology Interactions App

Pfizer wishes to provide support to Further Development and Maintenance of Oncology Interactions App and has therefore entered into this Agreement with Cancer Department at Aarhus University Hospital (hereafter referred to as the "Recipient").

The purpose of the activity is to further develop and maintain of Oncology Interactions application.

The agreement shall run from 1st November 2019 to 30th November 2019.

Pfizer's financial commitment in relation to this Agreement shall be **328.000 DKK** excl.VAT.

Pfizer will not provide any non-financial support.

Please complete and sign the attached Payment Form and return to Pfizer as soon as possible together with the signed agreement. Please note that Pfizer will be precluded from providing you with the financial support if you do not state a CVR-number on the Payment Form.

Responsible persons at the Hospital

The donation will be given to the Recipient and is accepted by Jørgen Frøkiær, Head of Department, Department of Clinical Medicine, Aarhus University.

Furthermore the support is approved by Anni Ravnsbaek Jensen, Chief Physician, Ph.D., Head of the Department of Oncology who is responsible for the hospital account to which the funding is paid to.

Disclaimer

The Recipient will ensure that the donation is used solely for professional and scientific purposes in relation to the activity and undertakes that any surplus from the donation not used in accordance herewith will be refunded.

Upon request from Pfizer the Recipient must document that the support is spent in accordance with the above-mentioned.

Furthermore the Recipient will be responsible for compliance with all applicable law.

Pfizer shall not be liable for damages of any kind and Pfizer provides no indemnification of any type.

WP2372422

Disclosure

This Agreement shall be publicly disclosed on Pfizer's webpage (www.pfizer.dk) when the Agreement is made and for a period of 2 years thereafter.

Data Privacy

By signing this Agreement the Recipient agrees that Pfizer archives information about the Recipient and persons employed with the Recipient, who are or have been involved in this agreement. The Recipient carries the responsibility, that the persons who are involved in the agreement are informed and accept the processing and transfer of personal data., including name, contact details, and CVR-no in a global electronic system for processing of personal data. The electronic data processing system is accessible for a number of companies within the Pfizer group. The personal data can be transferred by Pfizer to other companies within the Pfizer group, to business partners as well as relevant governmental authorities, when this is necessary. Such recipients can be situated in countries outside the EC, e.g. the United States (so-called third-countries). For transfers from the EEA to countries not considered adequate by the European Commission, we have put in place adequate measures, such as by ensuring that the receiver is bound by EU Standard Contractual Clauses, to protect your personal data. By signing this Agreement the Recipient agrees that Pfizer may transfer such personal data to third countries in order to fulfil this Agreement and for the purpose of precise identification of Pfizer's business partners.

The Recipient is entitled to contact Pfizer, if the Recipient wishes to access the processed personal information about the Recipient. The Recipient is further entitled to have the relevant information changed or deleted. This applies for all persons mentioned in this section.

WP2372422

The support is provided under the provisions set forth in this agreement and in accordance with Pfizer's Representations and Warranties (Appendix A).

By signing this Agreement the Recipient confirms to have read and understood Pfizer's Representations and Warranties pursuant to Appendix A ("Representations and Warranties") and that the support is spend in accordance with the above mentioned terms and conditions.

We kindly ask you to return the signed agreement to Pfizer.

Date: November 15, 2019


Signature of authorized signatory on behalf of Pfizer:

DocuSigned by:

BF78B64DE9B6406...
Stefano Podesta
Oncology Lead, Denmark


Date: November 15, 2019

Signature of authorized signatory on behalf of Department of Oncology, Aarhus University Hospital:

DocuSigned by:

59AAA5936407441...
Anni Ravnsbaek Jensen
Chief Physician, Ph.D.,

Accepted by:

Date: November 18, 2019

DocuSigned by:

758ED6888A8347B...
Jørgen Frøkiær, Head of Department,
Department of Clinical Medicine, Aarhus
University

Appendix A - Representations and Warranties

- 1.1 The financial support from Pfizer will not cause your entity and, to your knowledge, any individuals affiliated with your entity or this support, to do anything that would result in Pfizer improperly obtaining or retaining business or gaining any improper business advantage;
- 1.2 Neither your entity nor, to your knowledge, any individuals affiliated with your entity or this support, will use any portion of the financial support from Pfizer to directly or indirectly offer or pay any money or anything of value in an effort to influence any Government Official or any other person in order for Pfizer to improperly obtain or retain business or to gain an improper business advantage, and, have not accepted, and will not accept in the future, such a payment;
- 1.3 Pfizer may at any time publicly disclose that it has provided you with financial support, including the amount of such support; and
- 1.4 Pfizer will be entitled to revoke or suspend any financial support if Pfizer learns that your entity or any individuals affiliated with your entity or this support has used or intends to use any portion of the support to improperly seek to influence any Government Official or any other person in order to obtain or retain business or gain a business advantage.